Background: Tenofovir disoproxil fumarate (TDF) is commonly used for HIV treatment, but risk factors for tenofovir (TFV)-associated kidney disease are relatively understudied. Among a diverse cohort of HIV-infected women on TFV-based therapy, we performed intensive pharmacokinetic (PK) studies to measure TFV exposure and assess its association with subsequent kidney function.
Methods: The Women’s Interagency HIV Study (WIHS) is a multicenter, prospective cohort of representative HIV-infected women. Participants on TFV-based therapy (n=105) underwent 24-hour intensive PK sampling after witnessed dose under routine-use, steady-state conditions. Serial creatinine measures allowed assessment of kidney function (estimated GFR [eGFR] by the CKD-EPI collaboration equation) over the succeeding 7 years in all participants. Multivariable linear mixed models were used to evaluate the relationship between TFV area-under-the-time-concentration-curves (AUCs) at baseline with subsequent kidney function. Additional covariates adjusted for in the models include baseline age, baseline diabetes and hypertension, race, body mass index (BMI), ritonavir (RTV) use, duration of prior TFV exposure, CD4 cell count and viral load.
Results: The mean age of 105 participants was 43 (range 39-65) years; 63% were African-American, 25% Hispanic and 12% white. Baseline BMI was weakly positively correlated with eGFR (Ï=0.22, p=0.019) and negatively with TFV AUC (Ï=0.24, p=0.012). The figure shows the trajectory of eGFR over time by tertile of TFV AUC. The eGFR was significantly lower at baseline in the highest compared with lowest tertiles (mean ± SE) of TFV AUC (80 ± 4.3 vs. 104 ± 2.5 ml/min, p<.0001). By year 7, this difference had widened (72.4 ± 4.9 vs. 104.9 ± 2.9, p<.0001). After multivariable adjustment with baseline variables, the highest tertile of TFV AUC remained associated with significantly lower eGFR relative to the lowest tertile at both baseline (-15, 95% CI: -25 to -5, p=0.0047) and year 7 (-23, 95% CI: -34 to -12, p=0.0002). The association of TFV AUC with eGFR did not differ by BMI, concomitant use of RTV or age (tests for interaction p>0.1).
Conclusions: In this diverse group of women undergoing intensive TFV PK sampling, we found a strong and significant association between higher TFV exposure over time and faster declines in subsequent kidney function longitudinally. Variations in tenofovir drug exposure, although rarely assessed, may partially account for subsequent nephrotoxicity in HIV-infected patients.
Figure. Association of baseline tenofovir area-under-the-time-concentration-curves tertile with estimated glomerular filtration trajectory in 105 HIV-infected women.